Epilepsy drugs: Key market research findings
- Development of novel therapeutics drives market growth
- The Americas dominates the market geographically
- Key vendors – Eisai, GSK, Pfizer, and UCB
Technavio’s market research analysts predict the global epilepsy drugs market to grow at a CAGR of more than 4% between 2016 and 2020. The market’s growth can be accredited to the development of novel therapeutics using innovative technologies. Several technological advancements in the field of epilepsy drugs are resulting in the development of novel molecules. For instance, Aprecia Pharmaceuticals develops Spritam (levetiracetam) using the ZipDose technology, which uses a three-dimensional printing (3DP) platform. During 2015, the Americas dominated the global epilepsy drugs market by accounting for almost 51% of the overall market space. The high prevalence of the disorder and the treatment options in the region coupled with collaborations among local vendors is expected to boost growth in the epilepsy drugs market in the Americas during the forecast period.
The new market research report from Technavio presents a breakdown and analysis of the epilepsy drugs segments based on the spectrum of activity.
“Recently, there has been an increasing focus on the development of devices and smartphone apps to detect seizures and track medications. Seizure alert devices detect seizures and notify the event to physicians through alarms, phone calls, or text messages and sends out an alert warning to caregivers. Furthermore, vendors in the market are working on the development of new software that can efficiently stop the development of seizures even before they occur,” says Barath Palada, Lead Analyst, Pharma, Technavio Research.
The broad-spectrum anti-epileptic drugs segment was the primary revenue generator in the global epilepsy drugs market in 2015 with a market share of around 48%. Broad-spectrum anti-epileptic drugs treat both partial and generalized seizures. These drugs include levetiracetam, lamotrigine, phenytoin, topiramate, felbamate, zonisamide, valproic acid, and phenobarbital.
The prominent vendors in the global epilepsy drugs market include Eisai, GSK, Pfizer, and UCB. The global epilepsy drugs market is characterized by vendors such as Pfizer, UCB, GSK, and Eisai. These vendors are actively pursuing strategic initiatives in terms of growth and profitability, which in turn is boosting their market share. Moreover, the augmented demand for third-generation drugs, such as Vimpat (UCB) and Fycompa (Eisai), will also contribute to this market’s growth. Due to the rapid developmental activities of pharma companies, the market has witnessed the launch of extended-release formulations such as Vimpat XR and Keppra XR.
A more detailed analysis is available in the Technavio report, Global Epilepsy Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
